Abstract: The present invention relates to a non-invasive method for assessing the presence and/or severity of a lesion in an organ of an animal, including a human, said method comprising carrying out at least one non-invasive test resulting in a value, preferably a score result, and positioning the at least one value or score result in a class of a detailed classification, such as, for example, a detailed classification based on population percentiles, or on a reliable diagnostic interval (RDI), to be crossed with another RDI. The present invention also relates to a device, preferably a meter, carrying out the non-invasive method of the invention.

Abstract: The invention relates to a method of diagnosing the presence and/or severity of a hepatic pathology and/or of monitoring the effectiveness of a curative treatment against a hepatic pathology in an individual, comprising the establishment of at least one non-invasive diagnostic score, in particular a diagnostic score for portal and septal fibrosis and/or an estimate score for the fibrosis area and/or an estimate score for the fractal dimension.

Abstract: The present invention relates to the field of epidermal repair. More particularly, the invention concerns the use of a molecule able to inhibit a heteromeric receptor comprising OSMR? as a subunit, for the preparation of a composition for inhibiting the expression of inflammatory factors by the keratinocytes. In particular, the invention concerns the use of antagonists and/or expression inhibitors of OSM, IL-17, TNF?, IL-31, IFN-?, and/or the OSMR? subunit, for the preparation of cosmetic or dermatologic compositions, especially for treating inflammatory skin diseases. Methods for obtaining in vitro or animal models of skin inflammation diseases are also disclosed. These models can be used for screening molecules to find new drugs to prevent or treat psoriasis and other dermatitis.

Abstract: The present invention relates to a useful method for preparing nanocapsules having a liquid lipid core and a solid shell and charged with at least one active agent having a hydrophilic character, said method comprising at least the steps consisting in: i) providing at least a first microemulsion having a water-in-oil character, stabilized by at least one lipophilic surfactant and containing in its hydrophilic phase at least one active agent having a hydrophilic character, providing at least a second microemulsion, separate from the first microemulsion, formulated by phase inversion of an emulsion and stabilized by at least one heat-sensitive, nonionic hydrophilic surfactant; iii) adding said first microemulsion to said second microemulsion under conditions propitious for the formation of a novel microemulsion architecture in which said hydrophilic active agent remains present in the hydrophilic phase of the first microemulsion; and iv) chill-hardening the mixture formed in the previous step, so as to obtain n

Abstract: The present invention relates to a method and apparatus for deconvolving a noisy measured signal obtained from a sensor device (100), said noisy measured signal (y(t)) being the sum of the convolution product (x(t)N(t)) of an input signal (x(t)) of the sensor device, representative of a feature of physical quantity, by a convolution kernel (N(t)) defined by the response function of the sensor device (100) and a noise which interfere with the measure. The method is characterised in that said method comprises an estimate computation step (400) in the course of which a minimal estimate (xmin(t)N(t)) of the convolution product of the input signal by the convolution kernel of the sensor device is computed in order that said minimal estimate stays below the noisy measured signal (y(t)) and has at least one point in common with the noisy measured signal (y(t)).

Abstract: The present invention relates to a non-invasive method for assessing liver fibrosis progression in an individual, said method comprising the steps of calculating the ratio of fibrosis level to cause duration and to a non-invasive method for assessing liver fibrosis progression in an individual, said method comprising the steps of measuring, at two different times t1 and t2, the fibrosis levels FL (t1) and FL (t2) and calculating the ratio FL (t2)?FL (t1) to (t2?t1) and to a non-invasive method for assessing if an individual is a slow, medium or fast fibroser.

Abstract: A method for the in vitro diagnosis of an autoimmune immune response in an individual by detection, in a biological fluid from said individual, of antibodies directed against the pentraxin 3 (PTX3) antigen, characterized in that the presence of antibodies directed against the PTX3 antigen (anti-PTX3 antibodies) are determined in a biological fluid from the individual, and kits for implementing the method.

Abstract: An in-vitro non-invasive method for quantifying the lesions of the liver of the patient with metabolic steatosis addressing a diagnostic target, i.e. fibrosis, steatosis and/or steato-hepatitis (NASH) and measuring at least one marker selected from the group consisting of biomarkers and possibly clinical markers and possibly scores, the biomarkers being selected from the group consisting of glycemia, AST (aspartate aminotransferase), ALT (alanine aminotransferase), AST/ALT, AST.

Abstract: This invention relates to method of diagnosing the presence and/or severity of a liver pathology and/or of monitoring the effectiveness of a curative treatment against a liver pathology in an individual, leading to a score, comprising the combination, of at least one blood test and of at least one data issued from a physical method of diagnosing liver fibrosis, said data being selected from the group consisting of medical imaging data and clinical measurements, said combination being performed through a mathematical function. This invention also relates to a method wherein the combination through a mathematical function, of at least one blood test and of at least one data issued from a physical method of diagnosing liver fibrosis, is performed at least twice and the at least two resulting scores are combined in an algorithm based on the diagnostic reliable intervals.

Abstract: The invention concerns nanocapsules, in particular with an average size less than 50 nm, consisting of an essentially lipid core liquid or semiliquid at room temperature, coated with an essentially lipid film solid at room temperature having a thickness of 2-10 nm. The invention also concerns a method for preparing same which consists in producing a reverse phase of an aqueous emulsion brought about by several temperature raising and lowering cycles. Said lipid nanocapsules are particularly designed for producing a medicine.

Abstract: The present invention relates to the field of epidermal repair. More particularly, the invention concerns the use of a molecule able to activate a heteromeric receptor comprising OSMR? as a subunit, for the preparation of a composition for activating in vitro and/or in vivo keratinocyte migration and/or the expression of anti-microbial peptides by the keratinocytes. In particular, the invention concerns the use of OSM and/or IL-17 and/or TNF? and/or IL-31, or agonists thereof, for the preparation of cosmetic or dermatologic compositions.

Abstract: The present invention relates to a method for preparing poloxamer-protein particles. It also relates to poloxamer-protein particles obtainable by this method, dispersion thereof, and their use in methods of encapsulation, in particular of microencapsulation.

Abstract: The invention relates to nanocapsules with a liquid lipidic core and a solid lipidic shell, the lipidic core being loaded with at least one water-soluble or water-dispersible ingredient, said ingredient being present in the form of a reverse micellar system.

Abstract: The present invention relates to a method for use in the preparation of nanocapsules which have a liquid lipid core and a solid lipid shell and which are loaded with at least one active agent, wherein said method comprises at least the steps consisting in providing a microemulsion formulated by phase inversion of an emulsion, providing a second composition, distinct from said microemulsion and completely or partly formed from at least one active agent, placing said microemulsion in the presence of said second composition under conditions suitable for the interaction of said active agent with said microemulsion and annealing said microemulsion having interacted with said active agent in such a way as to obtain said nanocapsules. The invention also relates to a corresponding kit.

Abstract: The present invention relates to methods for predicting or diagnosing a thyroid disease in an individual.

Abstract: The present invention relates to the field of epidermal repair. More particularly, the invention concerns the use of a molecule able to inhibit a heteromeric receptor comprising OSMR? as a subunit, for the preparation of a composition for inhibiting the expression of inflammatory factors by the keratinocytes. In particular, the invention concerns the use of antagonists and/or expression inhibitors of OSM, IL-17, TNF?, IL-31, IFN-?, and/or the OSMR? subunit, for the preparation of cosmetic or dermatologic compositions, especially for treating inflammatory skin diseases. Methods for obtaining in vitro or animal models of skin inflammation diseases are also disclosed. These models can be used for screening molecules to find new drugs to prevent or treat psoriasis and other dermatitis.

Abstract: The invention concerns biphosphonic compounds of formula (I); microbiological anti-contamination compositions containing same, and their use for preventing or limiting fixing of macromolecules, micro-organisms and biofilm on solid surfaces, such as metal or mineral surfaces.

Abstract: The invention relates to a neuroactive substance which is characterised in that it has formula (O), wherein R1, R2, R3 and R4 are identical or different and are methyl or ethyl radicals. Preferably, the neuroactive substance comprises 6S-acetyl-4R,5R-dimethyl-1R(10S)-epoxy-2R-hy-droxy-7R-acetoxydecahydro naphthalene which can be isolated from Rhytisma fulvum cnidaria. The inventive neuroactive substance can be used as a pharmacological reagent in research work and is also suitable for use in the fields of industry (insecticides) and health.

Abstract: The invention concerns an assembly of at least one electrical or electronic power supply component on a printed circuit board (10) characterized in that said or at least one electrical or electronic power supply component (30) is directly mounted in close thermal contact on a thermally conductive conduction board (20) itself mounted in an opening (13) comprised in said printed circuit board (10), the lugs (32) of said or at least one electrical or electronic power supply component (30) being connected directly on the printed circuit (10).

Abstract: The invention relates to a medicament containing the polyphosphonate compound of general formula (I) as an active ingredient.